APA (7th ed.) Citation

J, Q., M, T., X, W., L, S., H, S., V, F., & X, Y. (2026). Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: A BRAVO model-based evaluation. Frontiers in public health, 14, 1787562. https://doi.org/10.3389/fpubh.2026.1787562

Chicago Style (17th ed.) Citation

J, Qin, Tang M, Wang X, Shi L, Shao H, Fonseca V, and You X. "Cost-effectiveness of IGlarLixi Vs. IDegAsp in Individuals with Type 2 Diabetes: A BRAVO Model-based Evaluation." Frontiers in Public Health 14 (2026): 1787562. https://doi.org/10.3389/fpubh.2026.1787562.

MLA (9th ed.) Citation

J, Qin, et al. "Cost-effectiveness of IGlarLixi Vs. IDegAsp in Individuals with Type 2 Diabetes: A BRAVO Model-based Evaluation." Frontiers in Public Health, vol. 14, 2026, p. 1787562, https://doi.org/10.3389/fpubh.2026.1787562.